From expert opinion to evidence-based: Changes in the gold standard of primary brain tumour diagnosis

Journal of Pathology

Volumn 213, Issue 1, 2007, Pages 1-3

  Kros, J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Genetic aberration; Glioma; Primary brain tumour; Prognosis; WHO

Indexed keywords

ALKYLATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYC PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53;

ARTICLE; BRAIN TUMOR; CANCER GRADING; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL RESEARCH; CONSENSUS DEVELOPMENT; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG SENSITIVITY; EVIDENCE BASED MEDICINE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENOTYPE; GLIOBLASTOMA; GLIOMA; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; MEDICAL DECISION MAKING; MEDICAL EXPERT; NEUROECTODERM TUMOR; OBSERVER VARIATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; WORLD HEALTH ORGANIZATION;

BRAIN NEOPLASMS; CONSENSUS; CYTOGENETIC ANALYSIS; EVIDENCE-BASED MEDICINE; GENETIC MARKERS; GLIOMA; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548458184     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2201     Document Type: Article

References (8)

1. Kros JM, Gorlia T, Kouwenhoven M, Zheng P, Collins VP, Figarella-Branger D, et al. Panel review of anaplastic oligodendroglioma from EORTC trial 26951: assessment of consensus in diagnsis, influence of 1p/19q loss and correlations with outcome. J Neuropathol Exp Neurol 2007;66:545-551.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO Classification of Tumours of the Central Nervous System. IARC: Lyon, 2007.
3. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001; 60:248-262.
4. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988; 62:2152-2165.
5. Kros JM, Troost D, van Eden CG, van der Werf AJ, Uylings HB. Oligodendroglioma. A comparison of two grading systems. Cancer 1988;61:2251-2259.
6. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003; 97:1276-1284.
7. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-1607.
8. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.